Actively Recruiting
Study of Sparsentan to Treat Proteinuria Caused by VEGF Inhibitor Cancer Treatments
Led by Brigham and Women's Hospital · Updated on 2026-07-30
20
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating sparsentan, an endothelin-1 antagonist, to reduce high-grade proteinuria in patients with cancer who are treated with vascular endothelial growth factor inhibitors VSPIs. This single-center, open-label pilot study aims to assess the safety and efficacy of sparsentan compared to historical controls who did not receive the drug. The trial focuses on patients with new high-grade proteinuria related to their cancer treatment. Participants will receive sparsentan starting at 200 mg daily for 2 weeks, with a planned increase to 400 mg daily. After the 8-week treatment period, patients will return to their standard care. The trial compares changes in urine protein-to-creatinine ratio between those treated with sparsentan and matched historical controls who did not receive sparsentan. Safety and feasibility will also be evaluated during the study. Throughout the study, participants will have their urine protein-to-creatinine ratio measured from screening to week 8. Researchers will monitor for changes in proteinuria, interruptions or discontinuations of VSPIs, and resolution of proteinuria. The total participation includes screening and an 8-week treatment phase, with follow-up assessments to evaluate outcomes and safety.
CONDITIONS
Brief Title
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Research Team
S
Shruti Gupta, MD, MPH
A
Api Chewcharat, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here